QUEEN MARY UNIVERSITY OF LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1882-01-08

Employees: 1K

Market Cap: -

Website: http://www.qmul.ac.uk

Clinical Trials

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

Phase 2

Completed

Conditions: Primary Breast Cancer ER+ve
Primary Breast Cancer AR+ve TNBN

Interventions: Drug: Enzalutamide
Drug: Exemestane

First Posted Date: 2016-02-09

Last Posted Date: 2024-07-05

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 221

Registration Number: NCT02676986

Locations: 🇺🇸
MD Anderson Cancer Centre, Houston, Texas, United States
🇩🇪
Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany
🇩🇪
Evangelisches Waldkrankenhaus Spandau, Berlin, Germany

and more 38 locations

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: MPDL3280A

First Posted Date: 2016-01-25

Last Posted Date: 2024-11-04

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 96

Registration Number: NCT02662309

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France
🇫🇷
Hospices Civils de Lyon, Lyon, France
🇫🇷
Institut Claudius Régaud, Toulouse, France

and more 17 locations

Predictors of CIN Study Series 5.0:Stability Study in Vaginal Self-samples

Not Applicable

Completed

Conditions: Human Papillomavirus

Interventions: Other: Cervico-vaginal self-sample taken with first flocked swab
Other: Cervico-vaginal self-sample taken with a second flocked swab
Other: Cervico-vaginal self-sample taken with a HerSwab device

First Posted Date: 2015-12-07

Last Posted Date: 2023-06-15

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 60

Registration Number: NCT02622997

Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-12-02

Last Posted Date: 2022-09-26

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 60

Registration Number: NCT02620189

Locations: 🇬🇧
University College London Hospitals NHS Foundation Trust, Rheumatology Department, London, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom

and more 5 locations

Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy

Phase 2

Completed

Conditions: Hemorrhage
Trauma
Coagulopathy

Interventions: Device: VHA algorithm

First Posted Date: 2015-11-01

Last Posted Date: 2018-08-29

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 412

Registration Number: NCT02593877

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇱
Academic Medical Centre, Amsterdam, Netherlands
🇩🇰
Copenhagen University Hospital, Copenhagen, Denmark

and more 4 locations

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Phase 1

Conditions: Squamous Cell Lung Cancer
Non-squamous Cell Lung Cancer With KRAS Mutations
Non-squamous Cell Lung Cancer With Wild-type KRAS
Triple-Negative Breast Cancer

Interventions: Drug: AZD2014
Drug: AZD6244

First Posted Date: 2015-10-22

Last Posted Date: 2020-02-25

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 118

Registration Number: NCT02583542

Locations: 🇬🇧
Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom

and more 1 locations

Colonic Motility in Constipation and Ageing

Completed

Conditions: Ageing
Constipation

Interventions: Device: 3D-Transit system

First Posted Date: 2015-10-15

Last Posted Date: 2023-01-13

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 50

Registration Number: NCT02575742

Locations: 🇬🇧
Queen Mary University of London, London, United Kingdom

Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina

Phase 2

Active, not recruiting

Conditions: Cardiovascular Diseases

Interventions: Dietary Supplement: Beetroot Juice

First Posted Date: 2015-08-20

Last Posted Date: 2024-02-14

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 300

Registration Number: NCT02529189

Locations: 🇬🇧
William Harvey Research Institute, Barts and The London School of Medicine, London, United Kingdom

Enhancing Diagnosis and Prevention of Cardiovascular Disease in Newham by Integrated Use of Electronic Health Records

Not Applicable

Completed

Conditions: Cardiovascular Disease

Interventions: Other: Enhanced Health Check

First Posted Date: 2015-07-01

Last Posted Date: 2018-03-06

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 190

Registration Number: NCT02486913

Locations: 🇬🇧
Bart's Heart Centre, London, United Kingdom

Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

Phase 2

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: Apatorsen (OGX-427)
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-04-22

Last Posted Date: 2017-08-22

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 140

Registration Number: NCT02423590

Locations: 🇬🇧
Medway NHS Foundation Trust, Gillingham, Kent, United Kingdom
🇬🇧
Barts Health NHS Trust, London, United Kingdom
🇬🇧
University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

and more 17 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy